HC Wainwright reaffirmed their neutral rating on shares of Minerva Neurosciences (NASDAQ:NERV – Get Rating) in a research report sent to investors on Thursday, Benzinga reports. They currently have a $8.00 price target on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Minerva Neurosciences’ FY2027 earnings at ($1.86) EPS.
Separately, StockNews.com upgraded Minerva Neurosciences from a sell rating to a hold rating in a research report on Tuesday, March 7th.
Minerva Neurosciences Trading Down 8.0 %
NASDAQ NERV opened at $1.67 on Thursday. The business’s 50 day moving average is $2.18 and its two-hundred day moving average is $4.56. Minerva Neurosciences has a 12-month low of $1.26 and a 12-month high of $15.27. The stock has a market capitalization of $8.89 million, a price-to-earnings ratio of -0.28 and a beta of 0.07.
Institutional Investors Weigh In On Minerva Neurosciences
Minerva Neurosciences Company Profile
Minerva Neurosciences, Inc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. It develops Roluperidone for the treatment of negative symptoms in patients with schizophrenia and MIN-301 for the treatment of Parkinson’s disease.
- Get a free copy of the StockNews.com research report on Minerva Neurosciences (NERV)
- What the SVB Financial Collapse Means for U.S. Banks
- MarketBeat Week in Review – 3/6 – 3/10
- 2 Offshore Drilling Stocks Set to Extract Big Profits
- Three Staples Stocks With Double-Digit Upside Ahead
- Can Investors Trust Consumers to Lift American Outdoor Brands?
Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.